Best Viral Vector CDMOs in South Korea
· updated as new inspection, certificate, and trial data enters the platform
4
CDMOs tracked
3
Fully scored
1
With FDA records
1
FDA inspections
Viral vector CDMOs manufacture the three GMP-relevant vector platforms used in modern gene therapy and gene-modified cell therapy: adeno-associated virus (AAV), lentivirus, and adenovirus. Each platform has distinct process, containment, and analytics requirements, and CDMOs typically specialize in one or two platforms rather than all three. Platform is the first shortlist filter in any viral vector procurement decision.
This ranking aggregates every CDMO tracked as a viral vector manufacturer across the three platforms. For platform-specific rankings with process-critical detail (BSL-2 containment for lentivirus, full/empty capsid analytics for AAV, high-titre transient expression for adenovirus), use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors integrating vector supply with downstream cell processing (CAR-T, gene-modified HSC), the <a href="/modality/cell-and-gene-therapy">cell & gene therapy view</a> extends this list with cell therapy CDMOs.
FDA inspection outcomes across these CDMOs: 1 NAI (no action), 0 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (1).
Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
LB
Lotte Biologics
Incheon, KR · Syracuse, NY
|
83.7 | 100.0 | 1 insp · 0 GMP | — | 0 programs |
| 2 |
SK
SK pharmteco
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | Available | 0 programs |
| 3 |
HX
Helixmith
Seoul, KR
|
59.0 | — | — | — | 0 programs |
| — |
CdmoGen Co., Ltd.
Cheongju, South Korea
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Viral Vector CDMO
Vector platform match
First shortlist filter for any viral vector program is platform. AAV for in vivo systemic, lentiviral for ex vivo cell engineering, adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within.
Facility-level regulatory record on the platform
A CDMO's strong FDA record on AAV does not automatically de-risk their lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use, not the CDMO's aggregate score.
Analytics maturity per vector
Full/empty capsid separation for AAV, RCL testing for lentivirus, particle-to-infectivity ratio for adenovirus — each platform has non-negotiable release-testing requirements. A CDMO's qualified, validated assay panel for the specific vector is the single most under-appreciated cost driver in viral vector programs.
Capacity match to phase and dose
AAV early clinical runs at 50-200L, commercial at 1,000-2,000L single batch; lentiviral commercial supply is a narrower field with per-patient-dose economics. Confirm the CDMO's capacity headroom at your target phase before shortlisting — capacity constraints appear late and derail commercial launches.
What has driven South Korea's rise as a biologics manufacturing hub?
South Korea's biologics CDMO growth (2015-present) has been driven by three factors: (1) Samsung Biologics' massive Songdo capacity build (Plants 1-5 total >600,000L mammalian cell culture, one of the largest single-city concentrations of biologics capacity globally); (2) Celltrion's biosimilar-driven commercial capacity, exported globally; (3) national policy focus on biopharmaceutical export as a strategic industry. Korean CDMOs supplying US and EU markets typically hold MFDS + FDA + EMA certifications concurrently — the Signal Score's Quality Compliance pillar captures all three. For biologics programs specifically, South Korea offers commercial-scale capacity availability that is genuinely scarce in the US and EU.
How do Samsung Biologics and Celltrion compare on CDMO offerings?
Samsung Biologics operates primarily as a contract manufacturer (CDMO) with dedicated commercial biologics capacity at Songdo; Celltrion combines internal biosimilar development with CDMO services, with significant capacity dedicated to their own commercial products. For pure CDMO engagements, Samsung Biologics is typically the more scale-available option; for programs where biosimilar development experience is a plus, Celltrion's integrated model can add value. Both hold FDA and EMA certifications. Cross-check with the biologics CDMO ranking for the broader Korean biologics landscape and individual profile pages for facility-level detail.
South Korean CDMOs supplying US and EU markets — regulatory considerations
South Korean CDMOs supplying US and EU markets need active FDA and EMA GMP certifications on the specific facility. Both regulators have inspection experience with major Korean biologics sites, and inspection outcomes have generally been favorable. For programs supplying UK specifically, post-Brexit MHRA acceptance of MFDS + EMA-recognized inspections has continued under transitional arrangements — sponsors should confirm current MHRA policy at RFP stage. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so Korean CDMOs with cross-jurisdictional posture rank higher on this pillar than domestic-market-only competitors.
Viral Vector CDMOs — Frequently Asked Questions
Who are the top Viral Vector CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Viral Vector CDMOs include Lotte Biologics, SK pharmteco, Helixmith. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Viral Vector CDMOs have FDA inspection records?
CDMO Signal tracks 1 Viral Vector CDMO with FDA inspection records and 0 EMA/MHRA GMP certificates across the group.
What should I look for in a viral vector CDMO?
Match the vector platform first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, vector-specific analytics maturity, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific technical detail worth reading before finalizing a shortlist.
How many viral vector CDMOs does CDMO Signal track?
65+ CDMOs are tracked across the three GMP viral vector platforms — the union of AAV, lentiviral, and adenoviral manufacturers, deduplicated. Each is scored independently on the standard four-pillar Signal Score composite.
How is viral vector manufacturing different from mAb or recombinant protein biologics?
Viral vector manufacturing shares the mammalian cell culture upstream backbone with biologics but diverges sharply on downstream. Viral vector downstream requires enveloped/non-enveloped virus purification (chromatography, tangential flow filtration, ultracentrifugation) rather than protein A affinity capture. Analytics differ fundamentally — infectious titer and capsid analytics for viral vectors vs product-related impurities for biologics. Regulatory paths also differ: viral vectors carry additional biosafety review (RCL for lentivirus, adventitious agents for all platforms) beyond standard biologics.
Related modalities